Does a high arachidonic-acid-to-EPA ratio reflect a shift toward pro-inflammatory lipid mediator pathways and possibly greater pain sensitivity?

An AA:EPA ratio is best understood as a compartment-specific fatty-acid precursor marker, not a direct inflammatory or pain test. In an 83-year-old man, it may add mechanistic context to a broader pain and cardiometabolic assessment, but does not establish a cause of pain or a treatment target.

Mechanistic evidence

• AA and EPA compete for membrane incorporation and cyclooxygenase/lipoxygenase pathways. Thus, a higher AA:EPA ratio plausibly indicates relatively more AA substrate than EPA in the sampled compartment.
• EPA supplementation can lower tissue AA:EPA and alter mediator profiles: in a 12-week trial, dermal EPA increased, AA:EPA decreased, and basal skin PGE₂ decreased.
• This ratio does not measure circulating eicosanoids or specialized pro-resolving mediators. Their production depends on tissue, cell type, enzyme activity, and inflammatory context. AA can also form pro-resolving lipoxins, while DHA—not EPA alone—contributes importantly to resolving-mediator families.
• Interpretation differs substantially between plasma, phospholipids, red-cell membranes, and disease-relevant tissue.

Pain-related evidence

• The pain link is biologically plausible but not established for AA:EPA specifically. In 605 adults, higher erythrocyte AA was associated with lower pressure-pain thresholds at five of six sites; however, EPA was not associated with thresholds, and AA/(EPA+DHA) was not associated with them.
• In a 35-day study of 41 women, fish oil lowered AA:EPA and tender-point counts but did not improve thermal or mechanical pain thresholds or other pain indicators. Cross-sectional associations between higher omega-6:omega-3 ratios and chronic-pain burden cannot establish causation.

Bottom line

• A high AA:EPA ratio may reflect a precursor balance more favorable to AA-derived lipid-mediator pathways and could be pain-relevant, but it is not a validated marker of inflammatory mediator output, pain sensitivity, or response to omega-3 treatment.